View clinical trials related to Cancer.
Filter by:The study is designed to evaluate whether ghrelin treatment can improve appetite in weight losing cancer patients.
To determine how safe denosumab is in treating subjects with giant cell tumor of bone (GCTB)
Study hypothesis: corticosteroids are effective for pain in cancer patients. We will perform a double-blind, randomized, placebo-controlled multicentre trial evaluating the effect of Methylprednisolone 16 mg twice daily in cancer patients with pain (average pain last 24 hrs NRS > 4 (Numerical rating scale, 0 No pain, 10 worst pain).
The purpose of this study is to assess the safety and tolerability of long term therapy with Sativex® and GW-2000-02.
This study will investigate how patients are informed of their cancer diagnosis or recurrence and will explore their experience in learning about the diagnosis. Specifically, it will: - Distinguish methods of telling the diagnosis and identify its relationship to the type of cancer. - Determine if the way a patient is informed of their diagnosis is associated with their level of satisfaction with the method of being informed. - Identify who informs the patient of their diagnosis.. - Determine patient satisfaction with their diagnostic consult. - Identify indicators of satisfaction with the diagnostic consultation. Patients 18 years of age or older who are enrolled in or being screened for enrollment in a phase I, II or III clinical trial in the National Cancer Institute's Medical Oncology, Metabolism, Surgery or Neuro-Oncology branch may be eligible for this study. Participants complete a 15-minute questionnaire that includes questions related to the how they were informed of their cancer diagnosis.
The purpose of this study is to determine whether Sativex® and GW-2000-02 are effective in the management of subjects with intractable cancer-related pain.
Two large homocysteine-lowering B-vitamin intervention trials have been performed in Norway during the period 1998 to 2005, NORVIT and WENBIT. The main objective in these trials was to study the clinical effects of homocysteine-lowering therapy with folic acid and vitamin B12 in patients with established coronary artery disease. Follow-up was terminated for NORVIT on Marc 31st 2004 and for WENBIT October 5th 2005, and none of the two trials proved any protective effect of the B-vitamin intervention on cardiovascular outcomes. There is so far no data on possible long-term effects following years of such B-vitamin treatment. Thus, the main objective of the combinded NORVIT-WENBIT study will will be to evaluate the long-term effect of the B-vitamin intervention on incident life-style diseases including cardiovascular disease, diabetes, osteoporotic fractures and cancer. A secondary object will be the identification of risk phenotypes or genotypes, and if such risk associations are midified by the B-vitamin intervention
The primary purpose of this study is to investigate the Dose Limiting Toxicities (DLTs), pharmacokinetics (PK), and pharmacodynamics (PD) of MK-2206 administered orally to participants with advanced solid tumors. The preliminary efficacy of MK-2206 will also be investigated.
This is a two-part study in subjects with hematologic malignancies designed to find the maximum tolerated dose (MTD) of GSK690693 (Part 1). Part 2 is designed to determine the efficacy of GSK690693 in a subset of subjects with hematologic malignancies.
Many types of chemotherapy may cause nerve damage as a side effect. This neurotoxicity can manifest as peripheral sensory neuropathy (characterized by numbness, tingling, or pain). The goal of this study is to determine the efficacy of the combination of vitamin B6 and B12 in preventing chemotherapy induced neuropathy.